Dead or alive is a binary outcome. 10 patients receiving Remestemcel-L survived, at a time when about 80 percent of patients on ventilators were dying.
No, it wasn't a RCT. Yes, there could have been something special about our patients other than the fact that they received Remestemcel-L. No, it isn't proof. But it if Remestemcel-L didn't contribute to this striking difference in mortality, it would be an incredible coincidence. This, along with other promising trials with stem cells, is why I am incredibly confident that our trial will be successful. (Look at the Pluristem compassionate use results for more encouraging evidence, albeit not "proof.") Common sense.
And don't lecture me on statistics. I graduated college in the top 1 percent of my class with a major in mathematics, and earned multiple graduate degrees that included courses in statistics.
.
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-206
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |